Loading data for SCNX — first visit, this takes a few seconds.

Alerta

Scienture Inc. (SCNX)

NasdaqCM: SCNX · Precio en tiempo real · USD

0.46

-0.01 (-2.13%)

Al cierre: Aug 18, 2026, 8:00 PM

0.45

-2.60%

Premercado: 4:36 AM

-2.13% (1D)

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	18.76M
Ingresos (TTM)	821.32K
Beneficio neto (TTM)	-37.95M
Beta	n/a
EPS (TTM)	-1.98
Ratio PER (TTM)	n/a
Adelante PE	n/a
P/B (TTM)	0.28
P/S (TTM)	22.84
Earnings Date	n/a

Precio de venta	n/a
Volumen	525,504
Volumen medio (20D)	2,538,061
Abierto	0.46
Anterior Cerrar	0.47
Rango del día	0.44 - 0.48
Rango de 52 semanas	0.24 - 2.60
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	19 jul 2024

Acerca de SCNX

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left vent...

[Leer más]

Industria Pharmaceutical Retailers

Sector Healthcare

IPO Fecha Feb 6, 2014

Empleados 4

Bolsa de Valores NasdaqCM

Símbolo bursátil SCNX

Sitio web https://scienture.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Scienture fueron 431.61K, un aumento de 215.87% en comparación con 136.64K del año anterior. Las ganancias fueron -41.51M, una disminución de -557.9%.

Estados financieros

Sorpresa de resultados

Scienture ha publicado sus resultados trimestrales en Aug 13, 2026:

Ingresos de $56.33K falla las estimaciones por $0, con 449.08% Crecimiento interanual.

EPS de -0.07 supera las estimaciones en 0.02, con -Infinity% Disminución interanual.

Noticias

6 días hace · InvestorsHub

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

SCIENTURE has commercially launched REZENOPY, its 10 mg naloxone nasal spray, and fulfilled initial purchase orders to U. S.

6 días hace · Benzinga

EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US

Pharmaceutical firm Scienture Holdings, Inc. (NASDAQ:SCNX) on Wednesday officially initiated the commercial rollout of Rezenopy, a 10-milligram naloxone hydrochloride nasal spray. The company has succ...

2 meses hace · Benzinga

EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

Scienture Holdings Inc. (NASDAQ:SCNX) said Tuesday that its opioid overdose treatment Rezenopy (naloxone HCl) Nasal Spray 10 mg has been added to the formulary of a large national health plan, broaden...

5 meses hace · Associated Press Finance

BC-Most Active Stocks

Elong Power Holding Ltd. 79,546,080 0.0559

8 meses hace · TipRanks

Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

Scienture (SCNX) announced a strategic collaboration to expand national access to Arbli, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli is expected to be...

Página 1 de 2

Scienture Inc. (SCNX)